Pfizer Inc. (NYSE:PFE – Get Rating) – Investment analysts at SVB Leerink lifted their Q3 2022 earnings estimates for Pfizer in a report issued on Wednesday, June 22nd. SVB Leerink analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $1.91 per share for the quarter, up from their previous estimate of $1.86. SVB Leerink has a “Market Perform” rating and a $55.00 price target on the stock. The consensus estimate for Pfizer’s current full-year earnings is $6.61 per share. SVB Leerink also issued estimates for Pfizer’s FY2022 earnings at $6.69 EPS, Q1 2023 earnings at $1.47 EPS, Q2 2023 earnings at $1.41 EPS, Q3 2023 earnings at $1.56 EPS, FY2023 earnings at $5.90 EPS, FY2024 earnings at $4.99 EPS and FY2025 earnings at $4.70 EPS.
A number of other research analysts have also recently weighed in on PFE. Citigroup boosted their price objective on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research report on Tuesday, April 5th. Morgan Stanley assumed coverage on shares of Pfizer in a research report on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price objective on the stock. Barclays set a $52.00 price objective on shares of Pfizer in a research report on Tuesday, May 17th. Berenberg Bank set a $50.00 target price on shares of Pfizer in a research note on Friday, May 27th. Finally, The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a research note on Wednesday, May 25th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $57.26.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The business had revenue of $25.66 billion during the quarter, compared to the consensus estimate of $24.73 billion. During the same quarter in the prior year, the firm posted $0.93 EPS. The company’s revenue for the quarter was up 76.8% on a year-over-year basis.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were issued a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.26%. Pfizer’s dividend payout ratio (DPR) is currently 36.70%.
In related news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,126 shares of company stock worth $2,075,003. Corporate insiders own 0.05% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank OZK grew its stake in shares of Pfizer by 0.3% during the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock worth $4,067,000 after purchasing an additional 195 shares during the period. TimeScale Financial Inc. lifted its position in shares of Pfizer by 2.9% during the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 196 shares in the last quarter. Bath Savings Trust Co lifted its position in shares of Pfizer by 0.5% during the 4th quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock valued at $2,344,000 after buying an additional 200 shares in the last quarter. Fruth Investment Management lifted its position in shares of Pfizer by 0.7% during the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after buying an additional 200 shares in the last quarter. Finally, Winfield Associates Inc. lifted its position in shares of Pfizer by 0.9% during the 4th quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock valued at $1,273,000 after buying an additional 200 shares in the last quarter. 66.50% of the stock is currently owned by institutional investors and hedge funds.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.